BIOCIDAL POLYMERS FOR VIRAL INACTIVATION IN PLASMA

用于灭活血浆病毒的杀菌聚合物

• 批准号: 2712400
• 负责人: JEFFREY F WILLIAMS
• 金额: $ 7.26万
• 依托单位: HALOSOURCE CORPORATION
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-01 至 1998-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2712400
• 关键词: Vesiculovirus; antiseptic sterilization; biomaterial development /preparation; biomaterial evaluation; blood proteins; coagulation factor IX; coagulation factor VIII; encephalomyocarditis virus; method development; polymers; protein structure function; serum; virus infection mechanism

Viral contamination is a constant threat in the production of plasma and derived therapeutic proteins (1,2). Currently, a variety of decontamination measures is available, including Pasteurization, solvent/detergent treatments and u/v irradiation; none provides assurance of efficacy against the range of viral pathogens that may be present (3). New methods are needed. Recent advances in N-Halamine polymer chemistry permit creation of contact biocidal surfaces, expressing rapid, potent efficacy against bacterial and viral pathogens in fluid streams (4,5,6). In this study, the feasibility of using these polymers is explored, for inactivating both enveloped and non-enveloped viruses. Functional retention of certain plasma proteins will also be determined. Plasma suspensions of enveloped and non-enveloped viruses (Vesicular stomatitis VSV and encephalomyocarditis EMCV) will be passed through columns of N- halamine polystyrene polymers, and flow rates and contact times varied to establish a) parameters necessary to bring about a 6 log inactivation, b) retention rates of coagulation factors F IX, F VIII as indicators of the practical potential of the process. Results will be used to determine the suitability of the method for extended studies on a wide range of viral targets and plasma protein functions, with additional polymers in the N-halamine series. PROPOSED COMMERCIAL APPLICATIONS: Novel biocidal polymers with rechargeable antimicrobial activity may prove effective for inactivation of viruses in plasma, plasma protein preparations, and therapeutic proteins made through transgenic animal technology. Commercial applications of this approach by fluid stream or batch treatment with polymers could be developed for manufacturers and blood product processors. Use of such products could have a serious impact on the safety of biological agents derived from human blood and animal blood or body fluids.

病毒污染是血浆生产中的持续威胁 衍生的治疗性蛋白质 (1,2)。目前，各种 可以采取净化措施，包括巴氏灭菌、 溶剂/洗涤剂处理和紫外线照射；没有人提供保证 针对可能存在的一系列病毒病原体的功效 (3)。 需要新的方法。 N-卤胺聚合物化学的最新进展 允许创建接触式杀菌表面，表达快速、有效 针对流体流中的细菌和病毒病原体的功效 (4,5,6)。 在本研究中，探讨了使用这些聚合物的可行性 灭活包膜病毒和非包膜病毒。功能性 某些血浆蛋白的保留也将被测定。等离子体 有包膜和无包膜病毒的悬浮液（水泡性口炎 VSV 和脑心肌炎 EMCV）将通过 N- 柱传递 卤胺聚苯乙烯聚合物，流速和接触时间各不相同 建立 a) 导致 6 日志失活所需的参数， b) 凝血因子 F IX、F VIII 的保留率作为指标 该过程的实际潜力。结果将用于确定 该方法适用于广泛的扩展研究 病毒靶标和血浆蛋白功能，以及其他聚合物 N-卤胺系列。 拟议的商业应用： 具有可充电抗菌活性的新型杀菌聚合物可能 证明对灭活血浆中的病毒、血浆蛋白有效 通过转基因动物制备的制剂和治疗性蛋白质 技术。这种方法通过流体流或 可以为制造商开发聚合物批量处理 血液制品加工商。使用此类产品可能会产生严重的后果 对源自人体血液的生物制剂的安全性的影响 动物的血液或体液。